title: [Adenoid cystic carcinoma of the breast:report of 25 cases].
abstract: OBJECTIVE
  To explore the clinical features, management approach and treatment outcomes for adenoid cystic carcinoma (ACC) of the breast.
  
  
  METHODS
  The clinicopathological data of 25 patients with breasts ACC treated in our hospital from years 1990 to 2012 were retrospectively reviewed and their prognosis was analyzed.
  
  
  RESULTS
  The median age of these 25 patients was 53 years (ranged from 31 to 81 years). With the exception of one male case, all patients were female including 17 cases of postmenopausal women. The most frequent presenting symptom is breast lumps, most (48.0%) were in the upper outer quadrant and areola area of the breast. Core needle biopsy was performed in five patients. The specimen finding were adenoids in three and invasive carcinoma in two cases. Axillary lymph node dissection was performed in 23 patients. Only two patients had histologically positive lymph nodes (3 of 14 and 2 of 20). Expression of ER and PR in 14 cases was detected by immunohistochemistry, showing one PR-positive and three ER-positive cases. The median follow-up of the 25 cases was 118 months (ranged from 12 to 244 months). Two patients died of lung metastases at 3 and 10 years after the surgery, respectively.
  
  
  CONCLUSIONS
  Due to the complexity of the histology of ACC, adequate sampling of specimens is essential for accurate diagnosis. ACC of the breast is a rare disease with a relatively good prognosis. The low incidence of axillary lymph node metastasis suggests that axillary node dissection is not recommended as a routine procedure. Breast ACC are often with negative ER and PR expression, and the value of adjuvant therapy needs to be further investigated.
authors.affiliation: The Cancer Prevention Center, National Clinical Research Center for Cancer, Cancer institute and Hospital of Tianjin Medical University; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Wei
authors.affiliation: The Cancer Prevention Center, National Clinical Research Center for Cancer, Cancer institute and Hospital of Tianjin Medical University; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Liang
authors.affiliation: The Cancer Prevention Center, National Clinical Research Center for Cancer, Cancer institute and Hospital of Tianjin Medical University; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Shixia
authors.initials: S
authors.lastname: Li
authors.affiliation: The Cancer Prevention Center, National Clinical Research Center for Cancer, Cancer institute and Hospital of Tianjin Medical University; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Email: ljt641024@163.com.
authors.forename: Juntian
authors.initials: J
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy / Q000379:methods*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate